A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Inclusion Criteria: * Signed written informed consent * Diagnosis of RCC with clear-cell or predominant clear-cell histology * Subjects with non-metastatic disease (M0) fulfilling any of the following combinations of pathologic staging based on American Joint Committee on Cancer (AJCC) TNM staging version 2010 and Fuhrman nuclear grading. * pT2, G3 or G4, N0; or, * pT3, G any, N0; or, * pT4, G any, N0; or, * pT any, G any, N1 * Fulfill all of the following criteria of disease-free status at baseline: * Had complete gross surgical resection of all RCC via radical or partial nephrectomy using either open or laparoscopic technique. * Baseline imaging of chest, abdomen and pelvis shows no metastasis or residual tumor lesions as confirmed centrally by an independent radiologist. * Received no prior adjuvant or neo-adjuvant treatment for RCC * Recovered from nephrectomy: any surgery related toxicities should be reduced to ≤ grade 1 per NCI Common Terminology Criteria for Adverse Events (CTCAE) (Version 4) * Karnofsky performance scale (KPS) of ≥ 80 * Adequate organ system function Exclusion Criteria: * History of another malignancy. Exception: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleed…